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ABSTRACT
In some breeds of dog, specifically the Yorkshire Terrier, a genetic defect exists that
causes a hepatic portosystemic shunt to form. A hepatic portosystemic shunt is a vessel that
when present cause blood to bypass the liver, which is responsible for filtering waste from the
digestive system and moving it out of the body. An implantable polymeric device was
constructed that would slowly occlude the hepatic portosystemic shunt and force the blood to
stop flowing through the bypassing vessel and flow through the vessel to the liver over 3-4
months time.
The portosystemic shunt occluder device consist of three polyoxymethylene components,
a swelling hydrogel (poly (acrylic acid)), and a degrading copolymer – (Poly (lactide-cocaprolactone)). The poly (acrylic acid) was used to move the piston component of the device
upward to constrict the portosystemic shunt placed inside the device. Eight milligrams of poly
(acrylic acid) had a swelling ratio of 20.10 ± 1.63, a swelling rate of 0.071 mm/s2, and generated
25mN of force. Eight milli-Newtons is the amount of force that is produced by blood flowing in
a four milli-meter diameter vessel.
The degradation properties of two compositions of poly (lactide-co-caprolactone) (40
percent lactide and 60 percent caprolactone; 86 percent lactide and 14 percent caprolactone)
were analyzed and relationships were developed that would aid in determining the degradation
rate of the copolymers in respect to the copolymer composition and the environmental
iii

temperature. The poly (lactide-co-caprolactone) controlled the rate that the piston moved by
providing a counter force to the poly (acrylic acid). The poly (lactide-co-caprolactone) (40:60),
when loaded into the device, degraded in 86 days in a phosphate buffered saline solution at a
temperature of 37oC.
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CHAPTER 1
PORTOSYSTEMIC SHUNTS
Background
The hepatic portal system is the system by which the blood flows through veins that
begin as capillary beds in the stomach, intestines, and spleen. As food passes through the
stomach and the intestines, Figure 1, certain nutrients are absorbed from it into the portal system.
Products excreted for digestion, such as bile acids, and produced by digestion, such as ammonia,
can also be reabsorbed into the portal system as well. But as the nutrients are absorbed, the
organs of the system also produce waste such as bile acids, ammonia, urea, and lipids. This waste
is then deposited back into the blood.
Blood constituents absorbed by the organs of the digestive system are filtered by the
liver. In a normally functioning system, blood that is processed by the liver is devoid of the
waste. In some dogs such as the Yorkshire terrier, a small breed of canine, they may lack the

Figure 1: Canine Digestive System [2]

proper function of the liver at birth.1 The impaired liver therefore makes removal of toxins
difficult.
Function of the Liver
The structure of the liver can be simply described as two inputs and one output. The
blood in the circulatory system enters the liver by way of two sources: the hepatic portal vein,
which transports oxygen deprived and nutrient rich blood, and the hepatic artery, which
transports oxygen rich blood, Figures 2 and 3. The portal vein is the main blood source to the
liver, Figure 2. Portal blood is derived from the capillary beds present in the stomach, intestines,
and the spleen, Figure 3 and 4. The portal vein is a combination between the superior mesenteric
vein, which originates from the digestive visceral, and the spleenic vein, which comes from the
spleen. After the portal vein enters into the liver it expands back into the capillaries, which then
release the blood into the liver and then filters the excess waste from the organs of the digestive
system. The filtered blood is absorbed back into the capillaries which pool to form the hepatic
veins, which drain into to the inferior vena cava, which flows to the heart and re-circulates the
blood, Figure 4 and 5.
Portosystemic Shunts
A portosystemic shunt is a blood vessel that allows blood to bypass the liver, move
directly into the inferior vena cava and heart, thus eliminating the participation of the liver. The
liver is the vital organ responsible for the body’s digestion, excretion, nutrient storage, nutrient

2

Figure 2: Major Vessels of the Hepatic Portal System [4]

Figure 3: Structure of the Liver [5]
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Figure 4: Canine Circulatory System [3]

Figure 5: Canine Heart
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conversion, detoxification, and synthesis of glycogen. More importantly, the constitutive cells of
the liver aid in the removal and storage of glucose from the blood, as well as lipids, vitamins,
copper and iron. The liver also removes elements such as ammonia and converts it into a safer
chemical form of nitrogen (i.e. urea), which is used to make proteins for cell growth and repair
and also creates the kidney concentration gradient for urine production. Excess ammonia is
excreted from the body by way of the kidneys. The liver also acts as a filter to prevent toxins
from reaching the heart that could lead to a potentially fatal condition of sepsis.
In dogs, the ductus venosus is a large portosystemic shunt that circumvents the liver
during fetal development. Portosystemic shunts are classified based on three categories: method
of development, structural integrity, and type of bypass. The development of portosystemic
shunts is classified as either congenital or acquired. Congenital shunts are vascular abnormalities
that are thought to occur with abnormal fusion or incomplete regression of embryonic abdominal
vasculature during fetal development or failure of normal closure after birth.6 The ductus venous
in normal dogs closes functionally within days and is structurally obliterated within 3 weeks post
birth.
Acquired portosystemic shunts occur as a response to improper function of the liver or
liver disease. For example, cirrhosis of the liver decreases its functionality and increases the
blood pressure in the portal system. Acquired shunts assist in diverting blood away from a
nonfunctional liver and protect a damaged liver from further deterioration. Congenital shunts are
more common than acquired shunts and have been noted to be genetically linked in breeds of
5

dogs such as Maltese, Irish Wolfhound, and particularly the Yorkshire Terrier. In a study
conducted by Karen Tobias at the University of Tennessee College of Veterinary Medicine, a
significant number of Yorkies seen in a 12 year period were diagnosed as having congenital
portosystemic shunts, and that percentage has been increasing over the past 10 years. This study
concluded that Yorkshire Terriers were 35.9 times more likely than other breeds to be born with
portosystemic shunts. The reason for Yorkshire predisposition is attributed to the amount of
inbreeding in the breed, hence why it is considered to be a hereditary disorder; but the
mechanism of inheritance has yet to be elucidated.6
Portosystemic shunts can be classified as extrapatic or intrahepatic, single or multiple,
and congenital or acquired. Structural classifications are based on the relative position of the
branching off of the shunt to the portal vein from the vena cava (Figure 6). If the base of the
shunt begins at the main portal vein and then flows directly to the inferior vena cava, the shunt is
classified as an extrahepatic portosystemic shunt (Figure 6(b)). Typically, these shunts can
achieve a diameter up to one centimeter in size. They theoretically develop from abnormal
anastomoses of the vitelline veins with the cardinal vessels, which form the tributaries of the
caudal vena cava and its prehepatic segment.6 If the base begins within the branching of the
portal vein and flows to the inferior vena cava, then it is classified as an intrahepatic
portosystemic shunt (Figure 6c). Intrahepatic portosystemic shunts are thought to develop from
incomplete closure of the ductus venosus or retention of segments of vitelline vessels that should
have degenerated.6
6

Figure 6: Types of Portosystemic Shunts
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Normal canine fetal hepatic structures (Figure 6(a)) are derived from the vitelline and
umbilical veins. In the fetus, fusion and degeneration of various sections of these vessels leads to
the formation of the hepatic sinusoids, portal system, and the fetal ductus venosus, which are
necessary for proper circulation and filtering of the blood.7 It should be noted that environmental
and genetic factors alone or in combination are theoretically thought to be responsible for shunt
development in canines, such as those which can be seen in Figure 7.
Portosystemic shunts are also classified by if there are single or multiple shunts present in
the system, Figure 8. For the purposes of this research, discussion will be restricted to the most
common portosystemic shunt in small canines, congenital extrahepatic single shunts.
To understand the nature of congenital portosystemic shunts, it is necessary to understand
their formation. Fetal development begins with formation of the zygote. Pregnancy is divided
into three periods: the germinal period, the embryonic period and the fetal period. After
fertilization, the blastocytes begin separation into the three main layers: endoderm, mesoderm,
and ectoderm. The circulatory system develops out of the mesoderm layer. During the germinal
period, the basic structure of the mesoderm layer begins to form.
Next the embryonic period marks the stage of organ development on a broad scale.
Because the organs are not fully developed, organ systems such as the circulatory system are not
capable of supporting the other organ systems through their own facilitation. Thus, the other
developing systems (i.e. skeletal and muscle) rely on the mother’s circulatory system to provide
the necessary nutrients and nourishment for growth. During this stage, shunts such as the ductus
8

Figure 7: Portosystemic Shunt in Canine

Figure 8: Single and Multiple shunt System

9

venosus allow the developing blood flow to bypass other developing and partially functional
organs. At this point in the fetal development, the organ systems that are within the fetus cannot
fully operate, and consequently, the fetus is dependent upon the mother’s working organs.
Shunts provide a way of directing blood away from not fully functional organs. The components
of the plasma (water, electrolytes, and proteins) are transferred to the fetus from the mother via
the umbilical cord, because at this stage the heart and liver of the fetus are not fully functional.
The mother’s liver does the work of filtering out toxins, storing sugar, and producing protein for
the unborn fetus. Therefore, these shunts are necessary to avoid disturbing the developing liver
of the fetus and to deliver the filtered blood nutrients to the fetus from the properly working
organs of the mother.8,9 During the fetal period, the organs more fully develop, and the fetus
becomes less dependent upon the mother’s organs. After birth, these shunts close to allow the
neonate to rely upon its own body functions independently of the mother. But in some situations
shunt closure does not occur.
In the past, there have been a number of approaches used to occlude these extrahepatic
shunts. In the early 1990’s, surgical ligation was the recommended treatment for congenital
portosystemic shunts.10 However, this simple technique has experienced many setbacks.
Mortality rates associated with surgical ligation reached percentages as high as 21%.10
Complications due to this intervention included portal hypertension, anesthetic complications,
portal vein thrombosis, or status epilepticus.10
Characteristics such as constant small stature, poor muscle development, seizures, quiet
10

demeanor, and behavioral abnormalities (circling, disorientation, unresponsiveness, staring into
space, head pressing) are common symptoms of dogs with extrahepatic shunts present. Dogs
with extrahepatic shunts normally have low blood urea nitrogen (BUN) and albumin
concentrations, display microcytosis (a condition where red blood cells are smaller than normal),
or acutely anemic. These blood related abnormalities permit diagnosis via blood analysis. The
urine analysis is also a method for detection. The amount of liver enzymes aspartate
aminotransferase (AST) and alanine aminotransferase (ALT) increases in dogs with congenital
portosystemic shunts resulting in small spiky crystals (ammonium biurate) in their urine also.
Though the previously mentioned symptoms/characteristics are visible in subjects with shunts
present, they are not specific to the presence of a liver shunt. Veterinarians use these
abnormalities as signs that a shunt could be the possible reason for the animal’s poor health. The
abnormal signs act as a clue indicating to test the bile acid or ammonia concentrations to evaluate
the livers function.9
Shunts can be treated with proper diet and medication, but only approximately one third
of the dogs medically treated will meet their average life expectancy. Over half the dogs that are
treated medically are euthanized within 10 months of being diagnosed because of neurologic
related problems, such as seizures and behavioral changes, or progressive liver damage.9
Many of the toxins produced in the intestines are due to the protein intake, therefore it is
important to reduce the amount of protein in the dog’s diet. Food for adults dogs and puppies
contain approximately 25% and 29% protein, respectively. In addition they also contain meat
11

byproducts. Dogs with shunts are restricted to high quality proteins made from vegetables or
milk that contains 18%-22% protein or less on a dry matter basis. The diet should also be rich in
antioxidants and vitamins, low in iron and copper, and easily digestible.9
One of the main medications that is prescribed to control the side effects of the shunt
being present is Lactulose, a disaccharide (fructose-galactose) solution that promotes diarrhea,
reducing the absorption of toxins.9 Intestinal bacteria produce most of the toxins that are
absorbed by the intestines. Lactulose changes the pH in the large intestines, decreases the
adsorption of ammonia and other toxins in addition to making the environment uninhabitable for
the bacteria that produces the toxins.9
In cases where the clinical signs are not controlled with the diet and/ or lactulose, the
veterinarian will normally prescribe antibiotics to reduce the number of toxin- producing bacteria
present in the intestines. Although diet and medicine are valid treatments the most effective
treatment that provides the best chance for a long and healthy life is surgery.9
Procedures for Shunt Occlusion
Silk Suture Ligation
A few investigators have reported successful occlusion of the congenital portosystemic
shunt, using a silk suture. Additional studies claim that complete occlusion is not controllable
using silk sutures.11 Silk, a non-absorbable material, is capable of inducing an inflammatory
response within a vessel wall. This is thought to be partially responsible for the occlusion effect
that occurs when a silk suture is utilized for vessel ligation in response to a congenital hepatic
12

shunt being present. Initially activated by the degranulation of the neutrophils a chronic
inflammation response (consisting of fibroblast infiltration, proliferation, and scar formation)
gradually occludes the vessel primarily around the time of application of the sutures.11,12 In a
study conducted by Youmans and Hunt, in which they tested the four primary vascular occlusion
methods ( Ameroid constrictors, cellophane, silk sutures, and transverse coil embolization) they
noted that silk sutures were the only method that failed to completely constrict the vein that was
being shrunk (attenuated) within a 6 week period.13
There are many factors that are thought to play a part in the rate of partial occlusion with
silk sutures: the degree of inflammation produced by perivascular dissection, excessive
manipulation of the vessel during surgery, postoperative vasospasms, as well as the diameter of
the suture being utilized.11,12,13 The advantages of using silk sutures as a treatment are (a) the
accessibility; (b) low cost, and (c) flexibility for application to both extrahepatic and intrahepatic
congenital portosystemic shunts. The disadvantages associated of silk sutures are: (a) require
measurement of intraoperative portal pressure during ligation; (b) potential secondary surgeries;
and (c) lack of complete occlusion of the vessel walls.11,13,14
Cellophane
Cellophane is derived from plant cellulose and it has a variety of purposes ranging from
reconstructive knee surgery to the attenuation of single extrahepatic shunts. The use of
cellophane bands for the attenuation of shunts in dogs began in since 1990. Sheets of sterile
cellophane are cut to form a layered band of a set width (dependent on the size of the shunt), then
13

the band is placed around the shunt. The cellophane initiates an inflammatory reaction around
the vessel that is generally associated with a chronic foreign body response. The inflammation
leads to gradual occlusion of the enclosed vessel.15,16,17 The use of cellophane banding to occlude
congenital extrahepatic portosystemic shunts is one of two methods currently accepted.
Treatment using cellophane is quick, inexpensive, with a long constriction time thereby
decreasing the chance of the developing portal hypertension.15,16,17
In a study conducted by Frankel et al. on 32 dogs, 18 cases evaluated retrospectively and
14 dogs evaluated prospectively, the results of the cellophane banding of the vessels showed the
technique resulted in complete occlusion of the attenuated vessels to a diameter 2.5 mm from an
initial diameter of 6.8 ± 1.4 mm diameter within an 8 week period. Vessels of an attenuated
diameter of 3.0 mm did not have 100% occlusion.16 They analyzed the results by reviewing the
medical history, hematologic and serum biochemical analyses, abdominal ultrasonography, and
portal angiography of the dogs. Frankel concluded that cellophane was a useful method in the
occlusion of vessels smaller than a 3 mm diameter.
Transvenous Coil Embolization
Transvenous coil embolization (TCE) is a process in which a coil (spring) is placed into a
shunt for gradual occlusion. A sheath is placed into the right jugular vein and a guided wire is
inserted into the sheath until it reaches the shunting vessel at which a stainless steel coil is
released to gradually occlude the vessel.14,15 The TCE method is less invasive and a more
convenient therapeutic resolution technique for congential intrahepatic portosystemic shunts but,
14

the down side to the process is that there are limited reports of successful treatments, especially
in small breeds of dog.14,15 Asano et al. have been successful in the application of TCE. They
tested the use of the transverse coil in a 3-month-old Miniature Dachshund. Two weeks after
implanting the 8-mm diameter coil in the 6 mm diameter vessel they noticed a reduction in the
serum bile acid levels and eventually complete occlusion after 4 months. The follow up study
conducted 3 years post implantation showed none of the associated clinical signs (decreased
function of the liver, weight loss, or hypertension). Therefore they concluded that transverse coil
embolization was successful, more so in larger breeds of dogs, after testing on a range of sizes.14
Ameroid Constrictors
An ameroid is hygroscopic compressed casein that swells when immersed in fluid. The
most effective treatment to date for gradual occlusion of a portosystemic shunt was done using
an ameroid constrictor. A stainless steel cuff, to withhold the stresses related to the expansion
(Figure 9), encases the occluder. The inner diameter of the shunt occluder was 5 mm, although
they are commercially available in size ranging from 3 mm to 10 mm. The locking mechanism
for the ameroid occluder (Figure 9) consists of a cylindrical peg, approximately 2 mm in
diameter for insertion into the ameroid disc. The Ameroid’s swelling capabilities facilitate a tight
fit between the ameroid and the lock. The placement of the Ameroid occluder in a surgical
operation is shown in Figure 10.
Results from original experiments using the occluder showed 14 % of the dogs died in
the early postoperative period from portal hypertension.10 In comparison to the surgical ligation
15

technique, the ameroid constrictor produces a suitable decrease in problems such as portal
hypertension, hemorrhage, or intractable seizures following recovery from anesthesia, which are
associated in up to 50% of dogs post-ligation.
In an experiment conducted by Vogt, they observed early rapid expansion during the first
14 days after implantation followed by 2 months of slow expansion.10 Inou et. al also conducted
a study to measure the expansion of an ameroid occluder. They recorded in the in-vitro study that
the ameroid expanded rapidly to 6% stenosis during the 24-hour period after immersion into
saline. The stenosis progressed slowly thereafter to 9% and 14% after 20 and 30 days
respectively. For the in-situ study the coronary stenosis progressed to 57 ± 14% (mean ± SD), 78
± 14%, and 58 ± 10% on the 10th, 20th, and 30th day post ameroid implantation (Figure 11).18,19
It was suggested that a more gradual approach to occlusion of the portosystemic shunt,
possibly 3 to 4 months, would be beneficial to the dog. Establishing a slower pressure change is
the main goal of this type of treatment. By having a slower gradual occlusion the pressure
change in the shunt is slowly changed, decreasing the major problems associated with rapid
vessel closure.6

16

Figure 9: Ameroid Occluder shown with a ruler

Figure 10: Hepatic Portosystemic Shunt w/ occluder placement

17

Figure 11: Ameroid Occluder Expansion in relation to Time [19]
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CHAPTER 2
DESIGN MATERIALS
The aforementioned shunt occluder designs (Ameroid occluder, silk ligation, and
cellophane banding techniques) all have flaws leading to outcomes that ranged from partial
occlusion to rapid occlusion and associated postsurgical issues such as hypertension. The goal of
this study is to design a new occluder that eliminates the problems associated with current
devices/ procedures. The proposed design is based on the use of hydrogels and degradable
polymers.
Hydrogels
Hydrogels are classified as crosslinked polymeric structures that swell during water
adsorption. They are normally made via a free radical polymerization mechanism, where
monomer units are connected into long chains through their double bonds. Crosslinking agents,
monomers with two or more double bonds, provide a polymer network structure by connecting
the long linear polymer chains. The crosslinked polymer chains contains either covalent bonds,
physical crosslinks from entanglements, association bonds, or strong van der Waals interactions
between chains.21 Hydrogels are classified into four categories: (i) homopolymer hydrogels, (ii)
copolymer hydrogels, (iii) multipolymer hydrogels, and (iv) interpenetrating polymeric
hydrogels. The classification is dependent on their method of preparation, physical structure or
ionic charge.21 Homopolymer-hydrogels are crosslinked networks of a single type of hydrophilic
monomer unit. Copolymer hydrogels are hydrogels that are produced by crosslinking two co19

monomer units, of which one must be hydrophilic to render the hydrogel swellable.
The degree of crosslinking in a polymeric network structure is a critical factor because it
dictates the mechanical strength, swelling ratio, and many other properties of the polymer gel by
influencing the molecular weight between crosslinks (Mc). The degree of crosslinking of a
polymer is controlled by the fractionation of crosslinking agents present in the copolymerization
and the double bond conversion in the reaction. Smaller amounts if crosslinking agent can lead to
a less densely crosslinked hydrogel.
The swelling of hydrogels is defined as the ratio of the volume of fluid to the volume of
solid inside the gel. The swelling ratio can be calculated using the following equation.

E SR (%)

WS W D
WD

100
Equation 1

ESR is the water absorption (wt %). Wd and Ws are the weights of the samples in the dry
and swollen states respectively.62 A polymer swells by water flowing into the spaces between
chains, which are created by the repelling of the ionic charges. Equilibrium is reached when the
polymer chains are separated by enough water molecules to negate their repulsive forces on each
other.24 The Swelling rate is the amount of displacement the network experiences over time,
Equation 2.
SR is the swelling rate, ΔX is the change in displacement, and Δt is the change over time.
It is an important factor because it is proportional to the rate at which a hydrogel network
20

absorbs a liquid.

SR

X
t

Equation 2

Poly (Acrylic Acid)
Polyacrylic acid (PAA) is a water soluble polymer. Its large absorbent capacity and nontoxic nature makes it a common material for use in menstrual pads and diapers. PAA has the
repeat unit molecular formula C3H4O2 and chemical structure depicted in Figure 12.
The network formation of the PAA hydrogel is made by a free radical polymerization
mechanism. The crosslinked structure of the ionic network is affected by the monomer
concentration, pH, and ionic strength during polymerization. A hydrogel network formed from
PAA has the ability to absorb many times their weight in water, or swell, and thus, is classified
as a super absorbant. The ability of PAA to swell is made possible by the carboxylic acid groups
on the polymer chain that associates strongly with water molecules. These types of group
interaction are influenced by ionic strength and pH, therefore the swelling equilibrium of the
PAA is influenced by the pH and ionic strength of the medium.23,24

Figure 12: Poly(acrylic acid) chemical structure [22]
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The molecular weight between crosslinks (Mc) dictates the mechanical strength, the
swelling ratio, and the swelling rate based on the length between the crosslinks. In the shunt
occluder, PAA will be used as a source of force to drive a piston to close the shunt. The force is
created by the expansion of the PAA when confined in a small compartment within the occluder.
Poly (lactic acid) (PLA)
Poly (lactic acid) (PLA) is a biodegradable linear polyester derived from lactic acid. The
structure of PLA is shown in Figure 13. Poly (lactic acid) is synthesized through a ring-opening
polymerization reaction (Figure 14). The methyl group adds to the more amorphous
characteristic as well as the increase solubility in organic solvents. The most commonly used
form is Poly(lactic acid) in the L-form -P(L)LA, which releases L-lactic acid, a component
common of the body, when it degrades.22
PLA degrades by homogeneous, hydrolytic erosion. Through hydrolysis and microbial
action PLA breaks down into carbon dioxide and water. PLA usually degrades in a two stage
process. In the first stage of degradation, the majority of the molecular weight loss occurs with
some loss of tensile strength. In the second stage, the mass and tensile strength decrease
significantly, generally when the number average molecular weight (Mn) is less than or equal to

Figure 13: Poly (lactic acid) chemical structure [22]
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Figure 14: Reaction Scheme of Poly lactic acid [25]

15000 g/mol. P(L)LA with a molecular weight of approximately 95000 g/mol degrades in vivo
by 56% over approximately a 6 month time span based on peak molecular weight (Mp) analysis
conducted by Wong. For Poly (DL Lactic acid) with a molecular weight of 58000 g/mol and
87000 g/mol, there is 49% degradation in vivo in one month, also based on the Mp According to
Wong.25
The glass transition temperature of the PLA ranges from 51-59oC, the melting
temperature ranges from 159-178oC, and the tensile modulus ranges between 1200-3000 MPa.
The tensile strength, degradation rate, and the melting temperature are dependent on the weight
average molecular weight and chemical structure (D or L structure).25
Poly lactic acid can be processed like most thermoplastics, into fiber using conventional
melt-spinning processes and film. PLA is currently used in a number of biomedical applications,
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such as sutures and drug delivery devices. It is also being evaluated as a material for tissue
engineering. Since it is biodegradable it can be used in the preparation of the biocompatible
polymers, useful for producing loose-fill packing, compost bags, food packaging, and disposable
tableware.
PLA has many potential uses in the form of fibers and non-woven textiles, such as
upholstery, disposable garments, awnings, feminine hygiene products, and diapers. It is an
odorless polymer and is classified as GRAS (generally recognized as safe) by the Food and Drug
Administration (FDA) in the United States. PLA can be synthesized to be either rigid or flexible.
Lactic acid can be copolymerized with other monomers to control degradation. The
mechanical properties of PLA, and its degradation behavior, make it an ideal polymeric
candidate for implants in bone or soft tissue, and also for resorbable sutures. In summary, the
mechanical, pharmaceutical, and degradation characteristics can be controlled by parameters
such as chemical composition and molecular weight of the polymer.26 The time frame for
resorption of the PLA and its copolymers may be as little as a few weeks or as much as a few
years. Major criticism of the polymer is that it releases carbon dioxide and methane during its
breakdown.
Poly(glycolic acid) (PGA)
Polyglycolic acid (PGA), Figure 15, is obtained from ring-opening polymerization of
glycolide. PGA is a highly crystalline, hydrophilic, linear aliphatic polyester that is
biodegradable. It has a melting point of 210oC at a Mw of 50,000 and low solubility in most
24

Figure 15: Poly (glycolic acid) chemical structure [25]

organic solvents. PGA has a glass transition temperature (Tg) between 35 -40oC. The degree of
crystallinity ranges between 46%-52% crystalline, depending on the crystallization temperature
(TC) and molecular weight (Mw).
PGA degrades mainly by bulk erosion. The erosion occurs by random hydrolysis of the
ester bonds. Erosion of PGA is a bimodal process. In the first phase there is diffusion of water
into the amorphous region which leads to hydrolysis. The second phase initiates after the water
penetrates and starts to hydrolyze the crystalline regions.43
PGA is used for the production of implantable medical devices and resorbable sutures.
Surgical sutures made from PGA show mass loss mainly in the second phase when water
penetrates into the amorphous region and complete degradation is achieved between 4 and 12
weeks. The rate of degradation is affected by the pH of the environment, degree of crystallinity,
and curing time.25 Degradation of PGA results in the production of glycolic acid which is nontoxic and is resorbed by the surrounding tissues, metabolized, and then is excreted as water and
carbon dioxide.25
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Poly (caprolactone) (PCL)
Poly (caprolactone) (PCL), Figure 16, is a biodegradable semi-crystalline aliphatic
polyester with a melting point of approximately 57oC and a glass transition temperature of 62oC.25 PCL can be prepared by ring opening polymerization of ε-caprolactone.
PCL is capable of forming copolymers and blends with a range of other materials. It
degrades by hydrolysis of the ester linkages and enzyme, which makes it an appropriate
biomaterial because these are methods of degradation in a biological environement.
The degradation process occurs in two-stages. The molecular weight loss occurs in the
first stage, by means of chain cleavage, and mass and strength loss occur in the second.43 The
degradation products of PCL are water and carbon dioxide. It is being considered as a potential
for long term implants, because of a slow degradation rate.25 PCL is used in drug delivery
devices, sutures, adhesion barriers and is being investigated as a scaffold for tissue repair.
Another application of PCL is a possible biodegradable contraceptive that can be placed under
the skin.

Figure 16: Poly (caprolactone) chemical structure [27]
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Figure 17: Poly (anhydride) chemical structure [25]

Poly(anhydrides)
Polyanhydrides are a hydrolytically unstable polymer. Polyanhydrides are characterized
by the bonds that they have to the R group. They are usually either aliphatic, aromatic, or a
combination of two. Polyanhydrides have been considered to be useful biomaterials as
carriers of drugs to various organs of the human body. A general structure of a polyanhydride is
shown in Figure 17. Polyanhydrides are very biocompatible, can be prepared easily from low
cost resources (such as dicarboxylic acid monomers with excess lactic anhydride), and can be
chemically modified to meet desirable end use applications. They degrade in vivo into non-toxic
di-acid counterparts that are eliminated from the body through one of the metabolic cycles. The
hydrophilicity of polyanhydride copolymers makes them unique in terms of biodegradability.
The anhydride bond is labile and rapidly hydrolyses in aqueous environments. However, water
penetration within the core of the polymer matrix is generally not allowed due to the
hydrophobicity, leading to primarily a surface erosion mechanism.27
Poly (lactide-e-caprolactone)
Poly (lactide-co-caprolactone), Figure 18, is a copolymer of lactic acid (LA) and epsiloncaprolactone. This polymer is produced by a ring opening polymerization of lactic acid and
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Figure 18: Poly (lactide-co-caprolactone) chemical structure [28]

epsilon caprolactone. The combination of these two polymers creates a biomaterial with more
potential applications than each homopolymer. The copolymerization of the lactic acid with
epsilon-co-caprolactone significantly increases its rate of degradation of the structure. Also,
biocompatibility is not an issue, as both copolymers have been proven to be extremely
biocompatible.
Poly (lactide-co-caprolactone) is not a widely used copolymer and does not have a known
history of biomedical applications. Though each of the polymers that constitutes the copolymer
are well known and historically used in biomedical applications, there is still a possibility of
unexpected events such as adverse reactions, mechanical property breakdown, and other
problems pertaining to concentration ratios. Using this polymer should entail a considerable
amount of testing. Also, protocols will have to be created to ensure consistency once a
concentration ratio is decided upon.
Copolymers are a strong choice in biomaterials because they offer flexibility and the
properties can be manipulated to meet specific needs. This is not only useful in controlling rates
of degradation but is also useful in managing desired properties such as benign byproducts.
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Copolymerization of two polymers extends control of the mechanical properties, including
tensile strength and modulus. The effect that copolymerization has on each of the individual
homopolymers is especially important. In the instance of poly (lactide-co-caprolactone),
copolymerization of the PLA with PCL increases the rate of degradation of the copolymer by
degrading the PLA portion of the copolymer faster and eroding the structure.
The biodegradable polymer’s degradation rate is very important therefore calculations
related to the composition of the polymers in the copolymer blend and molecular weights
associated with the polymer, which both are associated with the rate of degradation, have to be
determined to reach the goal of complete occluder constriction in 3 months. Further testing will
be required to obtain specific information of the relationship between the swelling of the
hydrogel and the degradation of the polymers, as depicted in Figure 18. The degradation of the
polymer and swelling of the hydrogel must be controlled to the point where the swelling and
degradation occur at complementary rates to cause the desired gradual occlusion. Poly (lactideco-caprolactone) seems to be the most appropriate degradable biomaterial for the new device
design.
Polyoxymethylene (Acetal)
Polyoxymethylene (Acetal), Figure 19, is a copolymer that is composed of Delrin (an
acetal homopolymer) and BASF Ultraform, (a cyclic ether). Polyacetal resins are implantable
high performance polymers that have high chemical and mechanical resistance. They are
commonly used in joint replacement components and other long term implants.30 Polyacetal,
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Figure 19: Polyoxylmethelene chemical structure [29]

mostly in a copolymerized form, has been used in in-vivo components, such as the Bjork-Shirley
tilting disc mechanical heart valve, for more than 20 years.31
The major advantage of having the copolymerized acetal is that it is stabilized. In
homopolymer form the polyacetal tends to depolymerize and eliminate formaldehyde. The
stabilization of the acetal is done by copolymerization with cyclic ether.31
The key properties of Acetron (polyoxcymethylene) are that it has high mechanical
strength, high modulus, high natural lubricity, excellent dimensional stability, and low moisture
absorption. A few of its uses are for bearings gears, electrical components, fuel system parts,
pulleys, anti-friction parts, and medical applications (i.e. bone joints and heart valves). Acteron
would be ideal because of its machining properties, its biocompatibility, and its certification by
the FDA, the USDA, NSF, Canada AG, and etc. It has a melting temperature of 168.33oC,
which is much higher than the temperature that it will be at in a biological environment (37oC). It
also has a Young’s Modulus of 400k psi, which is still well over the pressures necessary for
occlusion.
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CHAPTER 3
NOVEL DESIGN OF A PORTOSYSTEMIC SHUNT OCCLUDER

The previous studies have shown some promise in helping occlude portosystemic shunts
(Figure 6), but there are still complications due to the pressure changes that occur relatively
quickly after the treatments.11,12,14 The goal of this project is to design a shunt occluder with
variable occlusion rates. The initial objective is to design a device with a three-month linear
occlusion rate that would allow more time for the dog’s circulatory system to adjust to the
pressure changes caused by occlusion.
Materials Specifications
The material used for the shell of the device needs to be mechanically sturdy as well light
in weight. The selected materials for the new occluder must maintain structural integrity
throughout the life of the dog despite the (aqueous) environment in which it will be surrounded.
The selected materials must not elicit unfavorable reaction therefore they must have wellestablished biocompatibility in order to ensure the safety of the dog. Furthermore, the material
should be resistant to cell adhesion as this might impede the function of the device by blocking
the occluder piston’s motion or by encapsulating the device. The same material will be used for
the occluder’s piston. It needs to be smooth so as not to create friction to prevent the piston from
movement required to occlude the shunt.
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Materials
The shell of the device was a simple design. The cylindrical shell is made of two parts
that come together to encase the vessel, Figure 20. This design allows for the surgeon to load the
degrading polymer and swelling hydrogel into the device prior to surgery, which decreases actual
surgery time. The cylinder diameter is varied based on the size of the portosystemic shunt that is
to be placed in the vessel chamber. The casing is a polyoxymethylene material with the
trademark name Acetron. This material is used because of its FDA approved; it has sufficient
mechanical strength, and can be machined with ease.
Design
The new portosystemic shunt occluder (Figure 20) consists of three different sections: a
piston (Figure 21), a polymeric chamber (Figure 22), and a vessel chamber (Figure 23). For
assembly, the vessel chamber snaps together with the polymeric chamber and the piston is
suspended in between the two sections. The vessel chamber, a “ U ” shaped component that can
be seen in Figure 23, was designed for easy and comfortable placement of the shunt inside the
device.
The shape of vessel chamber decreases the possibility of pinching the targeted shunt
vessel, which could lead to blood disruption. Rapid blood flow disruption was determined to be
the reason that dogs with the Ameroid Occluder are at higher risk for hypertension, which leads
to the 14% mortality rate associated with the device. Check this percentage with newer papers.
The polymeric chamber is where the two desired polymers (the swelling hydrogel and the
32

(a)

(b)

Figure 20: Hepatic Portosystemic Shunt Occluder
(a) full device (b) occluder with polymers present
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Figure 21: Occluder's Piston

Figure 22: Polymer Chamber
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Figure 23: Vessel Chamber
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degrading polymer) are loaded, Figure 22. The third part of the device, the piston, was designed
to have unidirectional motion. The piston makes contact with the shunt and is directly
responsible for the occlusion.
The material from which the device is being constructed is polyoxymethylene. The
degrading polymer that is desired to control the piston’s motion was determined by its rate of
degradation, the byproduct, and loading capabilities in the design. The swelling polymer, that is
being used to provide the force necessary to close the shunt, was determined based on the
possible force that would be generated to move the piston.
Poly (DL lactide-co-caprolactone) (PLCL) was chosen as the degrading polymer because
of its surface-eroding mode of degradation as well as its slow rate of degradation. The PLCL will
be placed in the compartment adjacent to the swelling hydrogel, as can be seen in Figure 20.
The PLCL slowly erodes to impart the force from the swelling polyacrylic acid hydrogel
via the piston onto the vessel. Vert et al. found that the degradation of massive P(DL)LA and
P(L) LA specimens proceed more rapidly in the center than at the surface because of the
concentration of carboxylic acid end groups.32 PCL, an aliphatic polyester, provides good
permeation for steroids. It has a long degradation time that ranges between 3-5 years.32
Block PLCL, originally synthesized by Feng et al., has both the advantages of the
permeation rate of steroids and a degradation rate between that of the homopolymers (lactide and
caprolactone), which can be controlled by adjusting the composition of the copolymer.32
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Ye et al. conducted experiments to determine the degradation rate of PLCL in a
phosphate buffer solution at various temperatures and compositions. In Figure 24 the intrinsic
viscosity was analyzed for various compositions at different time intervals. There is a semilogarithmic relationship between the intrinsic viscosity [η] of homo- or block copolymers and
degradation time in phosphate buffer at the temperatures of 37oC, 45oC, and 55oC. PCL (ο)

as time progressed. As temperature increased the degradation rate increased. The intrinsic
viscosity in proportional to the molecular weight, higher molecular weight means a higher
viscosity.32
In a study using poly (lactide-co-caprolactone) (65:35) to make nerve guides. 80% of the
polymer had degraded after four months. The ability to alter and control the rate of degradation

Figure 24: PLCL Intrinsic Viscosity in respect to time [32]
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using different molar ratios of each copolymer is a very appealing characteristic. Tailoring the
degradation rate, and correlatively the occlusion rate, has the potential to eliminate previous
problems of hypertension due to spontaneous closure of the shunt.32
Design Overview
Figure 25 is an overview of the procedures for the hepatic portosystemic shunt occluder’s
testing. The three main sections are the device design, the polymer components, and the
complete mechanical system testing. There are two polymers that are being examined: the
swelling hydrogel polymer- Poly Acrylic Acid (PAA) and the degrading polymer-Poly (lactideco-caprolactone) (PLCL). The purpose of the PAA is to provide pressure to shift the piston that
will be in contact with the portosystemic shunt. The purpose of the PLCL is to control the rate at
which the piston will cause the vessel to occlude.
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Figure 25: Portosystemic Shunt Occluder's Project Flow Chart
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CHAPTER 4
EXPERIMENTAL
Materials
The PAA, the hydrogel for the experiment, was obtained from baby diapers. The
degradation polymers, Poly (DL lactide-co-caprolactone) (86 mol % lactide [457647-5G] and 40
mol% lactide [457639-5G]), were purchased from Sigma Aldrich. The molecular characteristics
for the PAA and the Poly (DL lactide-co-caprolactone) are presented in Tables 1.
Testing Procedure
The following are the studies that were performed to determine if the chosen polymers
experimentally had the desired characteristics (swelling ratio, generated pressure/force, and
degradation rates). The swelling testing was conducted using the thermal mechanical analyzer
(TMA) and the degradation studies were conducted using the gel permeation chromatographer
(GPC).
Degradation Studies
The purpose of the degradation studies was to determine the rate by which the Poly
(lactide-co-caprolactone) would molecularly degrade in an in vitro study that simulated a
biological environment (Temperature and pH).
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Table 1: Molecular characteristics of Poly (Lactide-co-caprolactone) and Poly Acrylic Acid
Poly(D,L Lactide- cocaprolactone) 86:14

Poly(D, L Lactide -cocaprolactone) 40:60

Poly Acrylic Acid

Transition Temperature

Transition Temperature

Transition Temperature

Tg -16oC

Tg- -39oC

Tm- 31oC

Inherent Viscosity

Inherent Viscosity

0.7 -0.9 dL/g

0.7 -0.9 dL/g

in chloroform (lit)

in chloroform (lit)

Tg-106oC

Mn-130,000
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Testing of Poly (lactide-co-caprolactone) (PLCL)
Approximately 25 mg of the PLCL was placed into a phosphate buffer saline (PBS)
solution that simulated a biological environment. The degradation rates were determined over a 6
week period for two samples of the PLCL in PBS sample solutions: one at 37oC, the temperature
of a biological specimen, and the other at 50oC to kinetically accelerate the degradation.
Preparation of Buffer Solution
Components:
Sigma Diagnostics- Phosphate Buffered Saline [pH 7.4 at 25oC]
Distilled water
1000mL container
Rubber stopper (for container)
Procedure:
Dissolve the contents of one PBS package into one liter of distilled water to get a pH
at 25oC
Verify the pH (with a Mettler Toledo Seven Multi pH meter with a Mettler Toledo
InLab413 NTC tip
Degradation of Polymer in PBS
Procedure
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Place 20mL of PBS into a 50mL container
Place 20mg of PLCL into each solution
Place container into an oven at a constant temperature of 37oC
Place the second container into another oven at a constant temperature of 50oC
Test the Molecular weight of the PLCL in a vile (37oC and 50oC) every two weeks,
for 8 weeks.
Characterization Techniques
Thermal Mechanical Analysis (TMA)
The thermal mechanical analyzer (TMA) is an instrument that can be used to measure
volumetric changes (the expansion or collapsing of a sample) in temperature controlled,
atmospherically inert environment (Figure 26). TMA studies can also be used to determine
characteristics such as: the glass transition temperature (Tg), the swelling ratio, swelling rate,
stress temperature relationships, and pressures produced by the samples.
The sample is placed in the instrument, in a thermally conductive container such as
aluminum, upon a stage that is made from a quartz glass. A rigid, thin plate is placed to partially
cover the sample within the crucible. The probe, also made of quartz glass, is placed in contact
with the surface of a plate. The probe and the stage are made from Quartz glass because it has a
relatively low, reproducible, and accurately known coefficient of thermal expansion. It also has a
low thermal conductivity that aids in isolating the sensitive transducer from the changing
temperature of the furnace. Once a sample is loaded the probe can apply a static force or a
43

Figure 26: Thermal Mechanical Analyser [33]
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dynamic force in addition to the initial desired load.
Gel Permeation Chromatography (GPC)
Gel permeation chromatography (GPC) is a experimental technique used to separate
mixtures according to a component’s molecular size. It consists of a mobile phase and a
stationary phase. The mobile phase, which is capable of mass exchange, is a liquid that can
readily dissolve the sample. The stationary phase is a porous material whose pore sizes are
various sizes and separates the molecules based on their particle sizes. Porous structures are
common in inorganic polymers (e.g. glass and silica gel) and in cross-linked organic polymers,
usually in the swollen state.8
In a simple example of using GPC, shown in Figure 27, the column is packed with the
swollen gel, a sample solution is poured in, and then the eluate is collected in fractions. The
solvent flows from the reservoir through a sintered glass plate into a device that is used for
degassing. The device is made up of an electrically heated metal block with an upright tube or a
Liebig condenser heated by a thermostat-monitored liquid. When water is the eluent a peristaltic
pump can be used, where as when the eluent is organic, piston pumps are more favorable. Also
aqueous solutions may be injected through elastomer packing, where as organic samples have
ball valves used instead.
GPC Testing Procedure


Slowly increase the flow rate of the instrument from 0.1 to 1.0 ml/min in 0.1
increments per minute and allow calibrating for 20 mins.
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Figure 27: Gel Permeation Chromatography Process [34]
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Completely dissolve sample (PLCL) in THF (Do not shake sample THF dissolves the
material that lines the lid). Weigh the sample so that for every 2.5mg of PLCL 1 mL
of Tetrahydrofuran (THF) is added


When completely dissolved add one (1) drop of toluene (Toluene use to monitor to
filtration process).



Clean syringe with small amount of sample possibly 0.2 mL and rotate syringe



Place more of sample in syringe and excrete until air bubbles are removed.



Place syringe filter on the tip of the syringe



Place sample in GPC and lock device.



Start Circus GPC/ Multi Detector Software Version 2



PL Data Stream Monitor (to monitor the data collection)
Testing of the Portosystemic Shunt Occluder

Testing of all the components associated with the shunt occluder (shunt occluder shell,
swelling hydrogel- PAA, and degrading polymer-PLCL) was necessary to verify complete
experimental function. The experimental setup can be seen in Figure 28.
A Pulsatile Blood Pump was used to simulate the fluid flow (flow rate, systolic and
diastolic pressure, volume) of a canine. A water reservoir was the fluid source (input) for the
blood pump. The output fluid of the blood pump flowed to a splitter which evenly divided the
pressure and flow of the fluid output from the blood pump. By dividing the fluid flow into two
different paths any shift or constriction to the synthetic vessel’s structure will decrease the fluid
47

Figure 28: Complete Device Testing
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five minute time period. The volume was measured in three separate trials per test date. Fluid
flow rate though the synthetic vessel, and correspondingly the volume of water collected in a set
flow ceased when the piston displacement was approximately 3mm. The vessel was constricted
to have a closed (constricted) thickness of approximately 1mm.
Procedure
Place PBS solution in beaker and then place the beaker on a heating plate
Set the temperature of the heating plate to 37oC
Place loaded (PAA and PLCL in the device) Portosystemic Shunt Occluder onto
synthetic vessel.
Connect synthetic vessel to fluid flow as presented in Figure 28
Place shunt occluder in PBS solution (make sure polymeric chamber is completely
submerged.
Turn on the Pulsatile Pump for a 5 minute interval
Collect water flow in separate beaker and measure with volumetric flask
Repeat test randomly as the portosystemic shunt occluder’s opening decreases ( note
the date and opening size)
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CHAPTER 5
RESULTS
Testing was conducted on three different areas of focus to characterized the polymeric
components of the shunt occluder: (1) the swelling hydrogel- poly (acrylic acid), (2) the
degradation the degradation of the polymer- poly (lactide-co-caprolactone), and (3) the shunt
occluder’s functioning. The pressure produced, the swelling ratio, and swelling rate of the poly
(acrylic acid) were determined using a Thermal Mechanical Analyzer. The molecular weight
degradation rate of two different compositions of poly (lactide-co-caprolactone) (40:60 and
86:14) were determined by analyzing several samples in in-vitro conditions (pH-7.4 and
temperature of 37oC ) and at an elevated temperature of 50oC. The final step of in-vitro testing
was to test the portosystemic shunt occluder with the polymeric materials loaded in the device,
Figure 20. The portosystemic shunt occluder, loaded with the poly (lactide-co-caprolactone) and
poly (acrylic acid), was tested in in-vitro conditions by analyzing the occlusions effect on fluid
volume change.
PolyAcrylic Acid
Approximately 8 mg of PAA was placed into a crucible of a 0.00533m diameter and a
0.00952m height. A constant force of 13.45 N/m2 was applied by the probe on the surface of the
plate, and the temperature was kept constant at 37oC in a nitrogen gas environment.
Figure 29 shows the curves obtained for five different swelling tests of the PAA: the
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Figure 29: TMA Swelling test of PAA
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information that can be obtained from this data includes the swelling rates, Table 2, and swelling
ratio, Table 3. The data shows that 8 mg of PAA will produce a maximum displacement of
approximately 5000 microns.
Swelling Rate of Poly(acrylic acid) Hydrogel
The swelling rates were determined for the PAA using equation 2. An average swelling
rate of 0.071mm/s was obtained for the PAA hydrogel (Table 2). The PAA hydrogel loaded into
the device would cause the piston to occlude a 4mm diameter vessel in 56.3 seconds, if the
opposing force produced by the degrading polymer (Poly (lactide-co-caprolactone)) wasn’t
present.
The swelling ratio of the poly (acrylic acid) was determined by the following equation:

V
Q

H

V

f
o

r 2H
r 2H

f
o

Equation 3

QH is the swelling ratio of a cylindrical shaped the poly (acrylic acid) hydrogel sample.
The radius of the vessel is r. Hf is the finial height of the hydrated poly (acrylic acid) in the
cylindrical crucible used to hold the sample during the TMA testing. Ho is the initial height of
the dehydrated PAA particles in the container. Table 3 summarizes the swelling ratios for five
measurements and the average value.
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Table 2: Swelling Rates of PAA Hydrogel
Trial 1 (mm/s)

Trial 2 (mm/s)

Trial 3 (mm/s)

Trial 4 (mm/s)

Trial 5 (mm/s)

0.0796

0.066

0.055

0.085

0.0696

Standard Dev

0.01176

Average

0.071
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Table 3: Poly (Acrylic Acid) Swelling Ratios
Trial 1
(mm/mm)

Trial 2
(mm/mm)

Trial 3
(mm/mm)

Trial 4
(mm/mm)

Trial 5
(mm/mm)

19.66

17.43

21.12

21.3

21

Average

20.1

StDev

1.63
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Degradation Studies of Poly (Lactide-co-Caprolactone) Copolymers
The degradation of two different molar compositions of poly (lactide-co-caprolactone)
were analyzed using TMA. As the copolymer degraded, by both random chain scission and
specific chain scission, the molecular weight of the polymer decreased. The decrease in the
molecular weight was monitored by analyzing the molecular weight by GPC of several PLCL
samples of different molar composition at different intervals of time (approximately every two
weeks) over a 42 day and 45 day period of analysis for the PLCL (40:60) and the PLCL (86:14),
respectively.
Poly (Lactide-co-Caprolactone) PLCL (40:60)
The PLCL with a molar composition of 40% Lactide and 60 % Caprolactone was placed
weight associated with the degradation of PLCL (40:60). The molecular weight degradation is
presented in respect to the molecular weight of the residual polymer in Tables 4 and 5.
The Poly (Lactide-co-caprolactone) (40:60) in the 37o C environment degraded at a
slower rate than the same composition, in the 50oC environment. After 42 days the PLCL
samples at the 37oC temperature were at approximately 50% of their initial molecular weight,
where as the PLCL samples at the 50oC temperature were degraded to approximately 18% of
their initial molecular weight.
Poly (Lactide-co-Caprolactone) PLCL (86:14)
The PLCL with a molar composition of 86% lactide and 14% caprolactone was in PBS
solution, as previously mentioned, and kept at two different constant temperatures, 37oC and
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Table 4: Degradation of Poly (Lactide-co-Caprolactone) (40:60) at 37oC
Degradation at 37oC
Days

Mw Trial 1

Residual 1 (%)

Mw Trial 2

Residual 2 (%)

1

44299.0

100.00

44602.0

100.00

13

35714.0

80.62

35760.5

80.18

28

26931.0

60.79

28337.5

63.53

42

22368.0

50.49

22520.5

50.49

Table 5: Degradation of Poly (Lactide-co-Caprolactone) (40:60) at 50oC
Degradation at 50oC
Days

Mw Trial 1

Residual 1 (%)

Mw Trial 2

Residual 2 (%)

1

57883.0

100.00

59106.0

100.00

16

43262.0

74.74

43705.0

73.94

30

19003.0

32.83

19070.0

32.26

42

10648.0

18.40

10737.0

18.17
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50oC, Tables 6 and 7 respectively. The PLCL (86:14) was analyzed using GPC to determine the
of molecular weight changes. The PLCL 86:14 composition degraded at a faster rate than the
PLCL (40:60) composition. In Tables 6 and 7, the percentage of the molecular weight that
remained with respect to the initial molecular weight, residual, decreased with time progression
of the two separate samples.
The degradation of the PLCL (86:14) was approximately the same at 37oC and 50oC. At
37oC, over a 45 day period of time, the polymer degraded to approximately 5% of its initial
molecular weight (Table 6) and at 50oC the PLCL (86:14) degraded to approximately 4% of its
initial molecular weight (Table 7). There was little difference between the degradation time of
the PLCL (86:14) at 37oC and 50oC.
Volumetric Fluid Flow through a Synthetic Vessel with an Occluding Portosystemic Shunt
Occluder Present
The loaded (with the degrading polymer poly (lactide-co-caprolactone) and swelling
hydrogel poly (acrylic acid)) portosystemic shunt occluder was positioned around a synthetic
vessel (Figure 20) and placed into a phosphate buffered saline (PBS) solution and kept at a
temperature of 37oC. The piston displacement, distance that the piston shifted to occlude the
vessel, was measured on the different days that the testing was performed. After the piston was
allowed to move a significant distance (≥ 0.5 mm) a fluid flow test was performed to determine
the change in volume of the water collected, Figure 28, as a result of the piston moving position
to seal off the vessel.
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Table 6: Degradation of Poly (Lactide-co-Caprolactone) (86:14) at 37oC
Degradation at 37oC
Days

Mw Trial 1 Residual 1 (%) Mw Trial 2 Residual 2 (%)

1

97128

100.00

96513.5

100.00

16

24890

25.63

24084

24.95

31

8248

8.49

7873

8.16

45

5142

5.29

4801

4.97

Table 7: Degradation of Poly (Lactide-co-Caprolactone) (86:14) at 50oC
Degradation at 50oC
Days

Mw Trial 1

Residual 1(%)

Mw Trial 2

Residual 2 (%)

1

97128

100.00

96513.5

100.00

16

15356

15.80

14778

15.31

31

6803

7.00

6437

6.67

45

3669

3.78

3342

3.46
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There was a decrease in the fluid volume flowing through the vessel over approximately
a 90-day period, at which time the flow was approximately zero (Table 8). Volume of fluid was
collected over a five minute intervals of time. The average volume of the collected fluid was
determined and the flow rate through the occluding vessel was determined using Equations 4 and
plotted in Figure 30. Table 8 shows the corresponding flow rates in perspective to the device
occlusion.

QR

Volume
Time

Equation 4

The distance between the piston portion of the portosystemic shunt occluder (Figure 21)
and base of the vessel chamber decreased over time and correlatively the flow rate decreased.
Figure 30 shows the average flow rates through the occluding vessel for several different days of
testing, up to a total of 86 days.

59

Table 8: Fluid flow testing of Portosystemic Shunt Occluder

* The time interval for each flow test was 5 minutes.

Fluid Flow through Occluding Vessel (In Vitro)

Flow Rate (mL/min)

300.00
250.00
200.00
150.00
100.00
50.00
0.00
0

20

40

60

80

100

Time (Days)

Figure 30: Fluid Flow Rate Through Occluding Vessel
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CHAPTER 6
DISCUSSION
Swelling of Poly (acrylic acid) Hydrogel
The analysis of the poly (acrylic acid) – PAA swelling properties was done using the
Mettler Toledo Star System TGA/SDTA851e Module Thermogravitational Analysis instrument.
The pressure and swelling characteristics of the PAA were determined from the TMA analysis,
Figure 29. PAA behavioral insight on how the swelling hydrogel would behave in the shunt
occluder device was gained. Small opaque gel balls, that were soft and easily broken when
rubbed between fingers, were formed when the PAA particles were hydrated. A set amount of
unhydrated PAA was placed in a small capsule with a flat plate that acted as a contact surface for
the quartz glass probe, in the TMA. PBS was then placed into the container to initiate the
swelling of the PAA, Figure 26.
The swelling ratio of the hydrogel, polyacrylic acid, had been anticipated to be
approximately 40 X its original size based on research conducted by Elliott et al.37 However, in
testing the hydrogel (PAA-H), the swelling ratio exceeded approximately 20X the original size,
Table 3. The actual swelling ratio provided swelling results less than the theoretical but still
more than enough to shift the piston into the desired position. The swelling rate of 0.071 mm/s
was obtained from the slope of the linear graphs in Figure 28.
The PAA generated a force greater 0.033N. The PAA had to overcome an applied force
of 33mN in the Thermal Mechanical Analyzer to move the quartz glass probe and obtain the data
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in Figure 29. This is more than the force of 0.025 N required to occlude the vessel and
significantly less than the force of 6.67 N that would cause mechanical failure of the device. The
force needed to cause mechanical failure of the device was determined by physically testing the
assembled device with loads (weights) applied. Mechanical failure occurred when a load of 24
oz (0.6805kg) was applied. Using equation 5 the force that was applied to the occluder device to
cause mechanical failure was 6.67.

P

P
o

F
A

Equation 5

Force Generated by Poly(Acrylic Acid) Hydrogel
The amount of pressure required to overcome the pressure generated by in a canine
circulatory system is approximately 0.002N/mm2 (15 mm Hg).7 The average shunt diameter is
approximately 4 mm2.7 With this knowledge we are able to determine the force required by the
swelling hydrogel (PAA) acting on the piston. The required force for the hydrogel to move the
piston a distance of 4mm can be determined by Equation 6.

Force mN

Area mm 2

F

F

Pr essure

N
mm 2

Equation 6

4mm 2
0.002 N
2
mm 2
25 mN

The force required to close the shunt in dogs is approximately 25 mN. The Force required
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for other diameters, within 3-10 mm, to occlude the vessel can be seen in Table 9. The swelling
ratios (QH) obtained from TMA investigation on multiple samples, are presented in Table 3.
The average swelling ratio (QH) of the polymer with 8 mg of PAA was 20.10 ± 1.63 mm.
The swelling ratio is determined from the height of the swollen PAA (Hf) divided by the height
of the unswollen PAA (Ho), Equation 3. The amount of swelling the PAA does determine the
piston displacement and rate of displacement. The swelling ratios in Table 3 are capable of
moving the piston (Figure 21) to occlude the vessel, depending on if the shunt is within the 3mm
to 10mm range (Table 9).
Molecular Weight Degradation
Degradation to the Poly (caprolactone) (PCL) portion of the copolymer occurs in two
ways, random chain scission and specific end chain scission. PCL undergoes degradation by pure
specific chain end scission by unzipping from the hydroxyl end of the polymer under isothermal
pyrolytic degradation and degrades thermally by random chain scission in solution.62 The PLA
portion of the polymer composition degrades with ester interchange processes and
decarboxylation from the chain ends.62
A copolymer of poly(Lactide-co-caprolactone) (PLCL) degrades at a faster rate than the
homopolymer. The decomposition temperature of PCL is 402oC, where as the decomposition
temperature of PCL/PLA copolymer is 350oC. One of the reasons for the faster rate of
degradation of the copolymer of PCL/PLA is because the lactide acid produced, as the PLA
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Table 9: Force required to Close a Canine Shunt
Force Required To Close a Canine Shunt
Shunt Size (mm)

Required Force

3

0.014

4

0.025

6

0.057

8

0.101

10

0.157
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degrades, influences the PCL63 A higher molar ratio of PLA in the copolymer composition leads
to more lactic acid production during the degradation of the polymer. This leads to an increase
the rate of degradation.
Poly (Lactide-co-Caprolactone) PLCL (40:60)
Gel Permeation Chromatography (GPC) results were obtained using a Polymer
Laboratory PL-GPC20 Integrated GPC System. Two PL-gel 5um mixed C 300 x7.5mm columns
were used in the instrument with a Knalier WellChrom K-2301 Refractive Index Detector. The
solvent used in the instrument was Tetrahydrofuran (THF).
The results presented in Tables 4 and 5 were obtained to determine the degradation rate
of the PLCL (40:60) at 37oC (the temperature in a biological environment) and 50oC (elevated
temperature to accelerate the degradation of the PLCL). Eight separate samples were prepared
and placed into separate containers. Four samples were prepared simultaneously and place in a
temperature controlled bath at 37oC and 50oC for each ratio. The molecular weights, Tables 4
and 5, decreased over the 42-day period.
PLCL (40:60), at 37oC, data extrapolated to 90 days (3 months) indicated a residual of
40.7 % of the degrading polymer’s initial molecular weight would remain for the targeted time of
the study, as shown in Table 10 and Figure 31. The PLCL (40:60), at a temperature of 50oC, was
predicted to degrade to 6.7% of its initial molecular weight after 90 days. The increase in
temperature acted as a catalyst to increase the rate of degradation of the PLCL. The degradation
at 37oC was compared to the rate of degradation of the 50oC. By comparing the two degradation
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Table 10: Degradation /Extrapolation of PLCL (40:60)

Day

PLCL Residual PLCL Residual
Mw Percentage at Mw Percentage
37oC (%)
at 50oC (%)

1

98.983

114.240

10

85.169

77.579

20

72.070

50.466

30

60.986

32.828

40

51.606

21.355

50*

43.669

13.891

60*

36.953

9.036

70*

31.269

5.878

80*

26.460

3.824

90*

22.390

2.487

*Extrapolated Data
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Percentage of Original Molecular
Weight (%)

y [37oC]= 100.65e-0.0167x ----37oC ----50oC
R2 = 0.9981
120

y [50oC] = 119.26e-0.043x
R2 = 0.9618

100
80
60

40
20
0

0

10

20

30

40

50

Time (Days)

Figure 31: Degradation Behavior of PLCL (40:60) Copolymers
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rates we could confirm proper degradation of the PLCL in the biological temperature of 37oC.
The effect of an elevated temperature in a biological environment, possibly due to an infection or
illness, on the device’s function (occluding of the shunt) could also be addressed.
Poly (Lactide-co-Caprolactone) PLCL (86:14)
The results in Tables 6 and 7 were obtained to determine the degradation of PLCL
(86:14) at 37oC and 50oC. Four samples were prepared simultaneously and place at 37oC and
50oC in a PBS Solution. The molecular weights decreased over the 45 day period. The initial
molecular weight of PLCL (86:14) (Table 6 and 7) was greater than that of the PLCL (40:60)
(Table 4 and 5).
The PLCL with a molar composition of 86% lactide and 14% caprolactone was also
placed in PBS solution, and kept at two different constant temperatures, 37oC and 50oC. The
PLCL (86:14) was analyzed using GPC to determine the of molecular weight degradation. The
PLCL 86:14 composition degraded at a faster rate than PLCL 40:60 composition. In Tables 11,
the percentage of the molecular weight that remained with respect to the initial molecular weight,
residual, decreased with time progression of the two separate samples.
The degradation of the PLCL (86:14) was approximately the same at 37oC and 50oC,
Figure 32. At 37oC, over a 45 day period of time, the polymer degraded to approximately 5% of
its initial molecular weight (Table 6) and at 50oC the PLCL (86:14) degraded to approximately
4% of its initial molecular weight (Table 7). There was little difference between the degradation
time of the PLCL (86:14) at 37oC and 50oC.
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Table 11: Degradation/Extrapolation of PLCL (86:14)
PLCL Residual

PLCL Residual

Mw Percentage

Mw Percentage

Day

at 37oC (%)

at 50oC (%)

1

82.984

71.962

10

44.837

37.138

20

22.624

17.807

30

11.416

8.539

40

5.760

4.094

50*

2.906

1.963

60*

1.466

0.941

70*

0.740

0.451

80*

0.373

0.216

90*

0.188

0.103

* Extrapolated data
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y = 88.859e-0.068x
R² = 0.9667

----37oC ---50oC

y = 77.451e-0.074x
R² = 0.9399

Percentage of Original Molecular
Weight (%)

120
100
80
60
40
20
0
0

10

20
30
Time (Days)

40

50

Figure 32: Degradation Behavior of PLCL (86:14)
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Comparison of Degradation Behavior of Copolymers
PLCL (40:60 and 84:16)
Sivalingam and Madras conducted a study to determine the thermal stability of a
copolymer composed of PCL and PLA. From their results they noted that the PCL degrades from
both random chain scission and specific chain end scission. The specific chain end scission leads
to the formation of e-caprolactone with volatiles such as CO2. Sivalingam and Madras also came
to the conclusion that at lower temperatures random chain scission dominates the degradation
process and as the temperature increases the specific chain end scission (from the hydroxyl chain
end portion of the chain) takes over and begins to dominate. This lead to the conclusion that
there is a change in degradation mechanisms in PCL as the temperature of the environment, that
it is placed in, increases.
For the current experiment, degradation studies of the PLCL were conducted at both 37oC
and 50oC for both compositions of the polymer (40:60 and 84:16). The theoretical prediction was
that the 40% lactide 60% caprolactone would degrade at a slower rate in both a biological
temperature (37oC) and in an elevated temperature (50oC). Figure 33 is a plot of the molecular
weight degradation of the two compositions at a temperature of 37oC. Figure 34 is a comparison
of the two different PLCL compositions (40:60 and 84:16) at 50oC. The theoretical prediction
for the PLCL (40:60) was correct, as can be seen by a plot of the molecular weight at the
different time spans. Though the PLCL (84:16) had a higher initial molecular weight than the
PLCL (40:60), Tables 4 and 6, the molecular weight of the PLCL (84:16) was less than that of
the PLCL (40:60) after approximately 13 days.
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Figure 33: Comparison of PLCL (40:60) and PLCL (86:14) at 37oC
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Figure 34: Comparison of PLCL (40:60) and PLCL (86:14) at 50oC
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The molecular degradation rate of the PLCL (40:60) composition was slower than the molecular
degradation rate of the PLCL (86:14) composition at an elevated temperature of 50oC. The PLCL
(86:14) degraded to 15.31% of its initial molecular weight after 16 days; where as the PLCL
(40:60) had only degraded to 73.94% of its initial molecular weight after the same amount of
time. The 40:60 has a slower and more desirable rate of degradation than the PLCL (86:14).
Effect of Temperature on the Molecular Degradation
Poly (Lactide-co-Caprolactone) (40:60)
As the environment’s temperature increases the rate of degradation also increase, Table
12.The effect of temperature on the molecular degradation rate of the poly (lactide-cocaprolactone) (40:60) polymer can be seen in Figure 35. At 37oC, after 10 days of degradation,
the PLCL (40:60) had a degradation rate of 1.38 g/mol/day; where as at the same time (10 days)
the PLCL (86:14) had a degradation rate of 3.67g/mol/day. The equation acquired, from
analyzing the data plotted in Figure 35, can be used to predict the molecular degradation rate of
the PLCL (40:60) at various temperatures.
It can also be seen that the degradation rate decreased as the composition of the polymer
degraded, Table 12. When the PLCL (40:60) was at 85.17% and 77% of its initial molecular
weights their degradation rates were 1.38 g/mol/day and 3.66g/mol/day, but at lower molecular
weights, 51.61% for the 37oC environment and 21.35% for the 50oC environment, the
degradation rates had decreased to 0.938 g/mol/day and 1.147 g/mol/day respectively.
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Table 12: Degradation Rates of Poly (Lactide-co-Caprolactone) (40:60) at 37oC and 50oC
Degradation Rate of PLCL 37oC

Degradation Rate of PLCL at 50oC

(g/mol/ day)

(g/mol/ day)

10

1.381

3.666

20

1.310

2.711

30

1.108

1.764

40

0.938

1.147

50

0.794

0.746

60

0.672

0.486

70

0.568

0.316

80

0.481

0.205

90

0.407

0.134

Avg

0.851

1.241

Days
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Molecular Weight Degradation Rate
(g/mol/day)

Effect of Temperature on Poly(Lactide-co-Caprolactone) Molecular Weight
degradation rate
y = 0.0301x - 0.2609
R² = 1
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1.2
1
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0.2
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Temperature (Celcius)

Figure 35: Molecular Degradation Rate in respect to temperature for PLCL (40:60)
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The degradation rate of the PLCL (40:60) had decreased by 32.1% within 40 days in the 37 oC
environment and by 68.8% within 40 days for the PLCL (40:60) in the 50oC environment.
Poly(Lactide-co-Caprolactone) (86:14)
The effect of temperature on the molecular degradation rate of the poly (lactide-cocaprolactone) (86:14) polymer can be seen in Table 13 and Figure 36. Unlike PLCL (40:60) as
the temperature of PLCL (86:14) increased from 37oC to 50CoC the degradation rate decreased
slightly, Figure 36. The effect of temperature on the molecular weight degradation rate for the
PLCL (86:14) was different from what was expected. The rate of degradation was expected to
increase as the temperature of the media increased. Unexpectedly, as the temperature of the
media increased the rate of degradation slightly decreased, Figure 36. The difference in the
molecular weight degradation rates were not significant enough (Table 13), therefore the effect
of temperatures between 37oC and 50oC on the PLCL (86:14) composition can be neglected.
Testing of the loaded Portosystemic Shunt Occluder
A synthetic vessel was placed into the portosystemic shunt occluder. The shunt occluder
was placed into phosphate buffer solution (PBS) that was keep at a temperature of 37oC. A
schematic of the experimental setup can be seen in Figure 28. As time progressed, the initial
shunt occluder diameter of 4mm decreased until the synthetic vessel was completely constricted.
Complete constriction was determined by a fluid flow of zero through the vessel, Table 8.
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Table 13: Degradation Rates of Poly (Lactide-co-Caprolactone) (86:14) at 37oC and 50oC
Degradation Rate of PLCL 37oC

Degradation Rate of PLCL at 50oC

(g/mol/ day)

(g/mol/ day)

10

3.814

3.482

20

2.221

1.933

30

1.120

0.926

40

0.565

0.444

50

0.285

0.213

60

0.144

0.102

70

0.072

0.049

80

0.036

0.023

90

0.018

0.011

Avg

0.919

0.798

Days
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Temperature Effect on the Molecular Degradation Rate of
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Figure 36: Molecular Degradation Rate in respect to temperature for PLCL (86:14)
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CHAPTER 7
CONCLUSIONS

The goal of this project was to develop an implantable device that would slowly occlude
a congenital single portosystemic shunt, which is a vessel in canines that is a genetic birth defect
that causes blood to bypass the liver, over a 3-4 month (90-120 days) time. The reason for
designing this device was because the current device that is used, the Ameroid Occluder, closes
the vessel too rapidly and as a result it causes the system in which it is implanted to develop
hypertension.. Hypertension results in development of multiple acquired shunts, which permit
continued diversion of portal blood around the liver instead of through it.
The new portosystemic device, that this project developed, was designed to be small
(varies based on the shunt size it is designed for), biocompatible (materials compatible with
biological system), light in weight (~1.15 g for a 4x4mm opening), simple (3 components, one of
which that moves), and most importantly able to occlude the portosystemic shunt over a 3-4
month (90-120 day) time span. The different components of the device (the swelling hydrogelPAA, the degrading polymer-PLCL, and the mechanical parts) were tested in separate stages.
The PAA had a swelling ratio of 20.10 ± 1.63 and a swelling rate of 0.071mm/s2. It
produces approximately 25mN of Force, which is more than the 8mN needed to occlude a vessel,
but less than the required force of 6.67N to cause mechanical failure of the device. The
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degradation polymer was predicted to molecularly degrade significantly so that the mechanical
properties of the polymer do not counter the force produced by the PAA after a 90 day time span
in a 37oC environment. When the complete device was tested, Figure 30, the device occluded the
synthetic vessel in 86 days. This is slightly shorter than the desired time range of 90 –120 days
but the molar composition of the degradation polymer can be adjusted to change the time of
occlusion.
Proposed Future Work
Additional testing needs to be conducted in an in-vivo environment before the device can
be marketable. The in vivo testing will be potentially conducted by Dr. Tobias with the
University of TN, School of Veterinary Medicine. The testing conducted thus far has been in
vitro and though it provides some incite to how the polymers and the device as a whole will
behave in the biological environment, it does not account for enzymatic degradation, foreign
body response, or the fluxing dynamic motions of a biological specimen. Animal testing needs to
be conducted in order to determine the system faults.
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